They said mid-year '18, meaning it could be on the market summer '19.
Which would be 2 years.
But anyway, not to pick nits.
It’s not the best news we could have, but the fat lady hasn’t yet sung.
1 Like
It will likely come onto market alongside a couple of other new sz drugs. Our options will really expand in the next 2-3 years!
2 years is a short time when talking about clinical trials.
1 Like
Yes, and did I read that Minerva Neurosciences would have some kind of an update later this week? There shouldn’t be clinical trials results yet, so not sure if it’ll be relevant to our interests, but there’s that, Evenamide and a few others.
1 Like
I just remembered, the bipolar trials will end around mid 2018. So there will be some more efficacy data then. Probably not a coincidence that the company would submit the NDA after that.
This are good news. Atleast the drug still has a chance of hitting the market. Hopeffuly it will be better than abilify and vraylar for negative simptoms? What do you people think? 
I’m wondering who is going to volunteer for the long term safety study, if the extension phase isn’t currently part of that. Given that the company hasn’t made public exactly what the issue with the animal study was. Not sure how people can make an informed decision if they aren’t provided with whatever information is available.
$15K average wholesale price
I guess I’ll just stay on Vraylar until this comes out or SND-12.
It’s good for your negative symptoms ? @insidemind
1 Like
Cheaper than that TD drug.
Cheaper than hospitalization.
What is the 15k wholesale price for?
One year of therapy with lumateperone.
Which is actually not that out there for a brand new antipsychotic. But pricey, yeah.
The price is what it would cost the insurance company, I think.
1 Like
It works pretty good.
1 Like